LYEL

13.8001.62%
WJ

William JL Rieflin

Independent Director

Mr. William JL Rieflin, also known as Bill, J.D., served as an Independent Chairman of RAPT Therapeutics, Inc. from June 2019 until January 3, 2025 and had been its Independent Director since May 2015 until January 3, 2025. He has been an Independent Director of Lyell Immunopharma, Inc. since May 2020. He serves as Independent Chair of the Board at Lycia Therapeutics, Inc. since September 2021 and serves as its Independent Director from December 2020. Mr. Rieflin had been a Director of NGM Biopharmaceuticals Inc. since October 5, 2010 and had served as the Chief Executive Officer of NGM Biopharmaceuticals, Inc. since October 5, 2010 until September 2018 and serves as its Executive Chairman of the Board of Directors since September 2018 until July 2022. Mr. Rieflin has experience in the biotechnology industry. Prior to NGM, Mr. Rieflin served as the President of Xenoport, Inc. from September 2004 to September 17, 2010 and served as its Secretary. He served as Strategic Advisor at NGM Biopharmaceuticals, Inc. until October 5, 2010. From 1996 to 2004, Mr. Rieflin held various positions with Tularik Inc. He served as Chief Financial Officer and Executive Vice President of Administration of Tularik Inc. since January 2001, Acting Chief Financial Officer since February 2003 and also served as its Acting Principal Accounting Officer. Prior to January 2001, he served as a Vice President, General Counsel and Secretary of Tularik Inc., since August 1996. Prior to joining Tularik, he served as Vice President of Human Resources, General Counsel and Secretary of AMSCO International Inc. from May 1992 to July 1996. He served as an Associate with the law firm Sidley & Austin and he served as a Sales Representative of American Hospital Supply Company. He is a Director of Lycia Therapeutics, Inc since 2020. He serves as a Director of Cumbre. He was an Independent Director of TriGemX Bio, Inc. (Formerly known as Kallyope, Inc.) since October 27, 2016. Mr. Rieflin has served on the Board of Directors of FLX Bio, Inc. since 2015. Mr. Rieflin also served as a board member of Flexus Biosciences until its acquisition in 2015. He served as a Director of Anacor Pharmaceuticals, Inc. from April 4, 2011 to June 24, 2016 and served as its Independent Lead Director from May 30, 2014 to June 24, 2016. He served as a Director of Xenoport, Inc. from September 17, 2010 to July 5, 2016. He earned his B.S. in Industrial and Labor Relations from Cornell University, his M.B.A. from the University of Chicago Booth School of Business and his J.D. from Stanford Law School.

Positions